nctId: NCT06319391 id: JSZ007 briefTitle: Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-01 date: 2024-05-01 date: 2025-10-01 date: 2024-03-20 date: 2024-03-20 name: Ziqiang Li class: OTHER briefSummary: Tacrolimus is the most commonly used immunosuppressant for preventing and treating rejection after liver transplantation. However, its treatment window is narrow, the pharmacokinetic individual differences are large, routine dose according to body weight, sometimes low dose will cause graft rejection of patients, or high dose will lead to infection and liver and kidney toxicity and other adverse reactions. Moreover, the conventional drug testing can not fully reflect the efficacy of tacrolimus, and there are shortcomings of lag, experience and passivity. FK506 is metabolized primarily by cytochrome P450 member 3A5 in the liver and intestines. CYP3A5\*3 is the most important factor determining the expression level of CYP3A5. This mutation can cause variable shear and produce unstable protein, so that patients carrying CYP3A5\*3/\*3 gene do not express CYP3A5. Acute kidney injury is a common and important complication after liver transplantation. Despite recent advances in organ preservation, surgical techniques, and immunosuppressive protocols, the incidence of AKI after orthotopic liver transplantation remains high. AKI has a significant impact on both short - and long-term prognosis of orthotopic liver transplantation recipients. Studies have shown that orthotopic liver transplantation recipients with AKI have significantly higher mortality rates in hospital, at 28 days and at 1 year after surgery than those without AKI. In this study, the relationship between donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration was investigated, and the effect of donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration on acute kidney injury after liver transplantation was investigated. To provide guidance for individual administration of gene-directed tacrolimus in patients, and provide basis for prevention and reduction of postoperative acute kidney injury in liver transplantation patients. conditions: Complete and Accurate Statistical Data of 60 Patients conditions: CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately conditions: Postoperative Tacrolimus Concentrations Were Accurately Recorded in 60 Patients conditions: According to the Diagnosis and Grading Criteria of Acute Kidney Injury, the Cases and Grading of Postoperative Acute Kidney Injury in 60 Patients Were Counted conditions: Scientific and Rigorous Statistical Analysis of Data studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 60 type: ESTIMATED name: CYP3A5*1*、CYP3A5*1*3 name: CYP3A5*3*3 measure: Fk506 measure: Scr sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital) city: Jinan state: Shandong zip: 250013 country: China lat: 36.66833 lon: 116.99722 hasResults: False